肿瘤源性外泌体在肿瘤骨转移中的作用机制与转化前景

doi:10.3760/cma.j.cn371439-20260123-00091

摘要/Abstract

摘要：

肿瘤源性外泌体（TEX）作为细胞间信息传递的核心媒介，通过携带微RNA、蛋白质、脂质等生物活性分子，在恶性肿瘤骨转移过程中发挥关键调控作用——既介导肿瘤细胞向骨骼的定向归巢，又参与骨转移前微环境的重塑，并驱动“肿瘤生长-骨破坏”的恶性循环。系统阐述TEX在恶性肿瘤骨转移中的具体调控机制，探讨其作为骨转移早期诊断标志物、靶向治疗靶点及药物递送载体的临床转化潜力，可为恶性肿瘤骨转移的精准诊疗提供新的策略与方向。

关键词: 肿瘤转移, 外泌体, 肿瘤微环境

Abstract:

Tumor-derived exosome （TEX） serves as a core mediator of intercellular information transmission and exerts pivotal regulatory effects on the progression of bone metastasis in malignant tumors by delivering bioactive molecules，including microRNAs，proteins，and lipids. It not only mediate the directed homing of tumor cells to the bone tissue，but also participate in the remodeling of the bone pre-metastatic microenvironment，and further drive the vicious cycle of "tumor growth-bone destruction". Systematically elucidating the specific regulatory mechanisms of TEX in bone metastasis of malignant tumors，and exploring its clinical translational potential as an early diagnostic biomarker for bone metastasis，a therapeutic target，and a drug delivery carrier，can provide new strategies and directions for the precise diagnosis and treatment of malignant tumor bone metastasis.

Key words: Neoplasm metastasis, Exosomes, Tumor microenvironment

张婕, 陈锦澍, 李园, 娄彦妮, 刘青. 肿瘤源性外泌体在肿瘤骨转移中的作用机制与转化前景[J]. 国际肿瘤学杂志, 2026, 53(9): 572-576.

Zhang Jie, Chen Jinshu, Li Yuan, Lou Yanni, Liu Qing. Mechanisms and translational prospects of tumor-derived exosomes in tumor bone metastasis[J]. Journal of International Oncology, 2026, 53(9): 572-576.

参考文献 37

[1]	Fujii Y, Yoshikawa R, Kashima R, et al. Evaluation of changes in activities of daily living and quality of life of patients with bone metastasis who underwent conservative therapy through bone metastasis cancer boards[J]. Medicina (Kaunas), 2024, 60(6): 906. DOI: 10.3390/medicina60060906.
[2]	Aliyev V, Guliyev M, Günaltılı M, et al. Comparative efficacy and cost-effectiveness of denosumab versus zoledronic acid in cancer patients with bone metastases[J]. J Clin Med, 2025, 14(18): 6469. DOI: 10.3390/jcm14186469.
[3]	He TT, Wang YN, Li XL, et al. Advancements in the study of exosomes in disease diagnosis and treatment[J]. Int J Pharm, 2026, 689: 126471. DOI: 10.1016/j.ijpharm.2025.126471.
[4]	Wang XR, Liu YF, Jiang YW, et al. Tumor-derived exosomes as promising tools for cancer diagnosis and therapy[J]. Front Pharmacol, 2025, 16: 1596217. DOI: 10.3389/fphar.2025.1596217.
[5]	Martínez-Espinosa I, Serrato JA, Germán-Valenzuela J, et al. Exosomal proteins as drivers of metastasis to distant organs[J]. Biomed Pharmacother, 2025, 193: 118886. DOI: 10.1016/j.biopha.2025.118886.
[6]	Liu CG, Luo YW, Zhou H, et al. Immune cell-derived exosomal non-coding RNAs in tumor microenvironment: biological functions and potential clinical applications[J]. Chin J Cancer Res, 2025, 37(2): 250-267. DOI: 10.21147/j.issn.1000-9604.2025.02.10.
[7]	Grigoryeva ES, Tashireva LA, Savelieva OE, et al. The association of integrins β₃, β₄, and α_Vβ₅ on exosomes, CTCs and tumor cells with localization of distant metastasis in breast cancer patients[J]. Int J Mol Sci, 2023, 24(3): 2929. DOI: 10.3390/ijms24032929.
[8]	Lin Q, Zong SW, Wang Y, et al. Breast cancer-derived CAV1 promotes lung metastasis by regulating integrin α₆β₄ and the recruitment and polarization of tumor-associated neutrophils[J]. Int J Biol Sci, 2024, 20(14): 5695-5714. DOI: 10.7150/ijbs.94153.
[9]	何光耀, 牛佳乐, 赵克晗, 等. 基于生物信息学分析整合素α11在胃癌组织中的表达及临床意义[J]. 肿瘤学杂志, 2025, 31(10): 865-871. DOI: 10.11735/j.issn.1671-170X.2025.10.B006.
[10]	Lin BQ, Lei YM, Wang JX, et al. Microfluidic-based exosome analysis for liquid biopsy[J]. Small Methods, 2021, 5(3): e2001131. DOI: 10.1002/smtd.202001131.
[11]	Yang RH, Jia L, Cui JW. Mechanism and clinical progression of solid tumors bone marrow metastasis[J]. Front Pharmacol, 2024, 15: 1390361. DOI: 10.3389/fphar.2024.1390361.
[12]	Kemna K, Van der Burg M, Lankester A, et al. Hematopoietic stem cell metabolism within the bone marrow niche-insights and opportunities[J]. Bioessays, 2025, 47(2): 2400154. DOI: 10.1002/bies.202400154.
[13]	Huang YF, Wang HL, Yue XM, et al. Bone serves as a transfer station for secondary dissemination of breast cancer[J]. Bone Res, 2023, 11(1): 21. DOI: 10.1038/s41413-023-00260-1.
[14]	窦子昂, 李淑琴. 乳腺癌转移前生态位的形成机制及研究进展[J]. 中国临床研究, 2026, 39(2): 315-319. DOI: 10.13429/j.cnki-cjcr.2026.02.030.
[15]	何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21(4): 313-325. DOI: 10.19438/j.cjoms.2023.04.001.
[16]	唐亮, 康辉, 吕成伟, 等. 肿瘤骨转移前微环境形成机制研究进展[J]. 精准医学杂志, 2022, 37(4): 370-374. DOI: 10.13362/j.jpmed.202204018.
[17]	Crunkhorn S. Making macrophages with anti-tumour activity[J]. Nat Rev Drug Discov, 2024, 23(4): 253. DOI: 10.1038/d41573-024-00045-z.
[18]	Yuan XX, Qian NS, Ling SK, et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells[J]. Theranostics, 2021, 11(3): 1429-1445. DOI: 10.7150/thno.45351.
[19]	Puppo M, Taipaleenmäki H, Hesse E, et al. Non-coding RNAs in bone remodelling and bone metastasis: mechanisms of action and translational relevance[J]. Br J Pharmacol, 2021, 178(9): 1936-1954. DOI: 10.1111/bph.14836.
[20]	He W, Wang Z, Li ZH. MicroRNAs in bone metastases: mechanisms and research progression[J]. Front Oncol, 2025, 15: 1552902. DOI: 10.3389/fonc.2025.1552902.
[21]	Hashimoto K, Ochi H, Sunamura S, et al. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A[J]. Proc Natl Acad Sci U S A, 2018, 115(9): 2204-2209. DOI: 10.1073/pnas.1717363115.
[22]	Tang Y, Pan J, Huang S, et al. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling[J]. J Exp Clin Cancer Res, 2018, 37(1): 160. DOI: 10.1186/s13046-018-0813-4.
[23]	Furesi G, De Jesus Domingues AM, Alexopoulou D, et al. Exosomal miRNAs from prostate cancer impair osteoblast function in mice[J]. Int J Mol Sci, 2022, 23(3): 1285. DOI: 10.3390/ijms23031285.
[24]	Fontana R, Mestre-Farrera A, Yang J. Update on epithelial-mesen-chymal plasticity in cancer progression[J]. Annu Rev Pathol, 2024, 19: 133-156. DOI: 10.1146/annurev-pathmechdis-051222-122423.
[25]	Elshimy Y, Alkhatib AR, Atassi B, et al. Biomarker-driven approaches to bone metastases: from molecular mechanisms to clinical applications[J]. Biomedicines, 2025, 13(5): 1160. DOI: 10.3390/biome-dicines13051160.
[26]	Xin ZF, Qin LY, Tang Y, et al. Immune mediated support of metastasis: implication for bone invasion[J]. Cancer Commun (Lond), 2024, 44(9): 967-991. DOI: 10.1002/cac2.12584.
[27]	Zhang Y, Liang JQ, Liu PL, et al. The RANK/RANKL/OPG system and tumor bone metastasis: potential mechanisms and therapeutic strategies[J]. Front Endocrinol (Lausanne), 2022, 13: 1063815. DOI: 10.3389/fendo.2022.1063815.
[28]	Htike K, Yoshida K, Eguchi T, et al. Herbal medicine ninjinyoeito inhibits RANKL-induced osteoclast differentiation and bone resorption activity by regulating NF-κB and MAPK pathway[J]. J Oral Biosci, 2024, 66(4): 49-57. DOI: 10.1016/j.job.2024.09.007.
[29]	Wen JY, Li BH, Wang SJ, et al. Bone metastasis: molecular mechanisms, clinical management, and therapeutic targets[J]. MedComm (2020), 2026, 7(2): e70604. DOI: 10.1002/mco2.70604.
[30]	Gottumukkala SB, Ganesan TS, Palanisamy A. Comprehensive molecular interaction map of TGFβ induced epithelial to mesenchymal transition in breast cancer[J]. NPJ Syst Biol Appl, 2024, 10(1): 53. DOI: 10.1038/s41540-024-00378-w.
[31]	Dabral P, Bhasin N, Ranjan M, et al. Tumor-derived extracellular vesicles as liquid biopsy for diagnosis and prognosis of solid tumors: their clinical utility and reliability as tumor biomarkers[J]. Cancers (Basel), 2024, 16(13): 2462. DOI: 10.3390/cancers16132462.
[32]	Li Y, Chen ZK, Duan X, et al. Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer[J]. Exp Mol Med, 2022, 54(9): 1379-1389. DOI: 10.1038/s12276-022-00856-3.
[33]	Lee JH, Won YJ, Kim H, et al. Adipose tissue-derived mesenchymal stem cell-derived exosomes promote wound healing and tissue regeneration[J]. Int J Mol Sci, 2023, 24(13): 10434. DOI: 10.3390/ijms241310434.
[34]	Zhang MH, Hu SY, Liu L, et al. Engineered exosomes from different sources for cancer-targeted therapy[J]. Signal Transduct Target Ther, 2023, 8(1): 124. DOI: 10.1038/s41392-023-01382-y.
[35]	Han L, Zhao ZR, He CS, et al. Removing the stumbling block of exosome applications in clinical and translational medicine: expand production and improve accuracy[J]. Stem Cell Res Ther, 2023, 14(1): 57. DOI: 10.1186/s13287-023-03288-6.
[36]	侯国姗, 袁辉明, 梁振, 等. 外泌体分离富集技术及其在疾病诊疗中的应用[J]. 色谱, 2025, 43(5): 434-445. DOI: 10.3724/SP.J.1123.2024.09007.
[37]	Zou YT, Zhou YP, Li GY, et al. Clinical applications of extracellular vesicles: recent advances and emerging trends[J]. Front Bioeng Biotechnol, 2025, 13: 1671963. DOI: 10.3389/fbioe.2025.1671963.